Sysmex's share price gained momentum from late October, with the upward revision to its first-half earnings forecast on 11/5 and strength in the Americas cited as the drivers.
Between 10/29 and 11/6, the share price rose from ¥1,929 to ¥2,065.5, recording a 7.1% gain over the period. Trading over the past five business days was driven primarily by earnings-related factors.
On 11/5, the company raised its consolidated net profit forecast for the first half of the fiscal year ending March 2027 to ¥17.0 billion and disclosed an impairment loss at the same time. Strength in the Americas was reported, indicating both factors supporting earnings and a one-time loss.
The share price was ¥2,017 on 11/5, up ¥72 from the previous day, and ¥2,065.5 on 11/6, up ¥48.5. Following the upward revision, the price rose in stages.
Trading volume on 11/5 was 3,316,400 shares, up 55% from the previous day. The simultaneous rise in the share price and increase in trading activity indicated more active price formation following the latest earnings revision.
The first-quarter earnings summary released on 8/7 reported revenue of ¥130.7 billion and net profit of ¥8.7 billion, representing substantial increases in both revenue and profit. Contributions from new domestic businesses and strong overseas hematology operations indicated the momentum behind the latest upward revision.
As of 11/2, analysts had lowered their forecast for ordinary profit for the fiscal year ending March 2027 by 0.2% from the previous week. Before the latest upward revision, analysts had also reviewed a previous downward revision, and the subsequent company revision updated market views of earnings.